HPLC Method For Analysis Of Ubrogepant in UBRELVY® Tablets on Newcrom R1 Column
https://sielc.com/hplc-method-for-analysis-of-ubrogepant-in-ubrelvy-tabletsChromatogram
Description
· High Performance Liquid Chromatography (HPLC) Method for Analysis of Ubrogepant .
Ubrogepant , also known as Ubrelvy®, is a newly discovered, calcitonin gene-related peptide receptor (CGPR) antagonist with the chemical formula C 29 H 26 F 3 N 5 O 3 . It is used for the acute treatment of migraine headaches. It is the first Calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Ubrogepant can be retained and analyzed using the Newcrom R1 stationary phase column. The analysis utilizes an isocratic method with a simple mobile phase consisting of water and acetonitrile (MeCN) with a sulfuric acid buffer. Detection is performed using UV.
Method Parameters
| Mobile Phase | MeCN/H2O – 40/60% |
|---|---|
| Buffer | H2SO4 – 0.1% |
| Flow Rate | 0.2 ml/min |
| Detection | UV 285 nm |
| Class of Compounds | Drug |
| Analyzing Compounds | Ubrogepant |
HPLC Column Used
Newcrom R1, 2.1 x 100 mm, 3 µm, 100 A, dual ended